Literature DB >> 9075604

Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM.

T C Friedman1, G Mastorakos, T D Newman, N M Mullen, E G Horton, R Costello, N M Papadopoulos, G P Chrousos.   

Abstract

Carbohydrate and lipid metabolism was cross-sectionally assessed in 16 patients with endogenous hypercortisolism (endogenous Cushing syndrome). Five patients (31%) had fasting glucose levels over 6.6 mmol/l and a HbA1C over 7.5%. Six patients (38%) had diabetes mellitus based on an abnormal 75 g oral glucose tolerance test (OGTT) and two additional patients (13%) had impaired glucose tolerance based on an OGTT. Compared to obese individuals, patients with Cushing syndrome had an elevated glucose but no elevated insulin response to the OGTT. Regression analysis showed positive correlations between 24-h urinary free cortisol (UFC) and fasting blood glucose (P < 0.0005), UFC and OGTT glucose area under the curve (AUC) (P < 0.01), and UFC and HbA1C (P < 0.005). UFC levels were negatively correlated (P < 0.05) with OGTT insulin AUC and insulin/glucose ratios. Eleven (69%) patients required anti-hypertensive therapy for blood pressure control. Total cholesterol and triglycerides were elevated in patients with Cushing syndrome compared to obese controls, while LDL and HDL cholesterol, and Lp(a) were similar in the two groups. We conclude that impaired glucose tolerance and/or diabetes in patients with endogenous Cushing syndrome is due to the hyperglycemic effects of cortisol with relative insulinopenia. Thus, Cushing syndrome shares features with both the Metabolic Syndrome X and NIDDM, including impaired glucose uptake, hyperlipidemia and hypertension. However, in Cushing syndrome, a relative insulinopenia occurs, while in Metabolic Syndrome X and NIDDM, insulin excess is observed. In Cushing syndrome, as the hypercortisolemia exacerbates, insulinopenia becomes more paramount, suggesting that cortisol exerts a direct or indirect "toxic" effect on the beta-cell.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9075604     DOI: 10.1507/endocrj.43.645

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  35 in total

Review 1.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

2.  Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids.

Authors:  F Delaunay; A Khan; A Cintra; B Davani; Z C Ling; A Andersson; C G Ostenson; J Gustafsson; S Efendic; S Okret
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

3.  Decreased glucose tolerance and plasma adiponectin:resistin ratio in a mouse model of post-traumatic stress disorder.

Authors:  T R Castañeda; R Nogueiras; T D Müller; R Krishna; E Grant; A Jones; N Ottaway; G Ananthakrishnan; P T Pfluger; N Chaudhary; M B Solomon; S C Woods; J P Herman; M H Tschöp
Journal:  Diabetologia       Date:  2010-12-22       Impact factor: 10.122

4.  Adrenoceptor-related decrease in serum triglycerides is independent of PPARα activation.

Authors:  Maria Konstandi; Kyriakos E Kypreos; Tsutomu Matsubara; Eva Xepapadaki; Yatrik M Shah; Kristopher Krausz; Christina E Andriopoulou; Aristeidis Kofinas; Frank J Gonzalez
Journal:  FEBS J       Date:  2019-06-28       Impact factor: 5.542

5.  Organization and Integration of the Endocrine System.

Authors:  George P Chrousos
Journal:  Sleep Med Clin       Date:  2007-06

Review 6.  Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders.

Authors:  George P Chrousos; Tomoshige Kino
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

7.  Silencing Mediator of Retinoid and Thyroid Hormone Receptors (SMRT) regulates glucocorticoid action in adipocytes.

Authors:  Margo P Emont; Stelios Mantis; Jonathan H Kahn; Michael Landeche; Xuan Han; Robert M Sargis; Ronald N Cohen
Journal:  Mol Cell Endocrinol       Date:  2015-03-09       Impact factor: 4.102

Review 8.  Cushing's disease.

Authors:  Martina De Martin; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

9.  Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone.

Authors:  Vernon W Dolinsky; Donna N Douglas; Richard Lehner; Dennis E Vance
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

10.  Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients.

Authors:  René Baudrand; Cristian A Carvajal; Arnoldo Riquelme; Mauricio Morales; Nancy Solis; Margarita Pizarro; Alex Escalona; Camilo Boza; Gustavo Pérez; Angélica Domínguez; Marco Arrese; Carlos E Fardella
Journal:  Obes Surg       Date:  2009-08-19       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.